APRE

Aprea Therapeutics Inc

0.6808

Aug 13 • 3:24 PM ET -0.0022 (-0.32%)

Healthcare Biotechnology USA Nano NASD

Aug 12, 10:15 AMAprea Therapeutics Inc reports fiscal Q2 2026 results with non-GAAP EPS $-0.07 (+87% YoY) and revenue $253,000 (+114% YoY), beats EPS and revenue estimates

Peers: AIM BCDA BIVI GOVX JAGX KAPA KPRX CALC CVM NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	8.43M
Enterprise Value	-32.07M
Income	-12.31M
Sales	0.01M
Book/sh	3.10
Cash/sh	3.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Oct 03, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	843.27
P/B	0.22
P/C	0.20
P/FCF	-
EV/EBITDA	-
EV/Sales	-3206.73
Quick Ratio	13.55
Current Ratio	13.55
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.08
EPS next Y	-0.27
EPS next Q	-0.07
EPS this Y	85.23%
EPS next Y	6.14%
EPS next 5Y	46.08%
EPS past 3/5Y	88.77% 47.99%
Sales past 3/5Y	- -
EPS Y/Y TTM	53.42%
Sales Y/Y TTM	-99.38%
EPS Q/Q	87.40%
Sales Q/Q	-100.00%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	60.56% -100.00%

Insider Own	13.60%
Insider Trans	0.00%
Inst Own	38.68%
Inst Trans	-2.25%
ROA	-41.30%
ROE	-46.15%
ROIC	-31.40%
Gross Margin	-324.92%
Oper. Margin	-255025.52%
Profit Margin	-237362.80%
SMA20	6.07%
SMA50	-3.86%
SMA200	-20.96%
Trades

Shs Outstand	12.39M
Shs Float	10.70M
Short Float	0.38%
Short Ratio	0.42
Short Interest	0.04M
52W High	1.79 -62.03%
52W Low	0.55 24.23%
Volatility	10.20% 8.71%
ATR (14)	0.06
RSI (14)	52.69
Beta	1.53
Rel Volume	0.21
Avg Volume	97.76K
Volume	18,646

Perf Week	7.64%
Perf Month	-2.44%
Perf Quarter	-22.64%
Perf Half Y	10.99%
Perf YTD	-20.19%
Perf Year	-60.19%
Perf 3Y	-82.96%
Perf 5Y	-99.07%
Perf 10Y	-
Recom	1.00
Target Price	3.55
Prev Close	0.68
Price	0.68
Change %	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy	$37
Sep-29-20	Resumed	JP Morgan	Neutral	$25
Jun-22-20	Initiated	H.C. Wainwright	Neutral	$30
Apr-21-20	Initiated	Robert W. Baird	Outperform	$45
Oct-28-19	Initiated	RBC Capital Mkts	Outperform	$33
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight	$23
Oct-28-19	Initiated	JP Morgan	Neutral	$23

Aug-12-26 08:30AM	Aprea Therapeutics Announces Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-30-26 08:00AM	Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 (GlobeNewswire)
Jun-01-26 08:00AM	Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors (GlobeNewswire) -8.59%
May-13-26 06:30AM	Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-07-26 09:45AM	Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls (The Fly) +5.66%
10:15AM	Loading…
Apr-21-26 10:15AM	Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting (GlobeNewswire) -7.51%
Apr-01-26 08:30AM	Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement (GlobeNewswire) -7.75%
Mar-30-26 08:01AM	Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement (GlobeNewswire) +8.20%
08:00AM	Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial (GlobeNewswire)
Mar-16-26 08:00AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-18-26 02:02PM	Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars (Benzinga) +21.33%
08:00AM	Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial (GlobeNewswire)
Feb-17-26 08:00AM	Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-12-26 08:30AM	Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth (GlobeNewswire)
Feb-04-26 08:30AM	Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor (GlobeNewswire)
08:27AM	Loading…
Jan-29-26 08:27AM	Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan (GlobeNewswire) -22.78%
08:25AM	Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-19-26 05:14AM	New Strong Sell Stocks for January 19th (Zacks)
Jan-14-26 04:21AM	New Strong Sell Stocks for Jan. 14 (Zacks)
Dec-18-25 08:30AM	Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 (GlobeNewswire)
Dec-09-25 08:30AM	Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.80%
Nov-12-25 08:30AM	Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
Oct-24-25 08:30AM	Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 (GlobeNewswire) -7.89%
Oct-15-25 08:00AM	Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies (GlobeNewswire)
Oct-14-25 08:00AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-28-25 08:30AM	Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-12-25 08:00AM	Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
Jun-25-25 09:00AM	Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center (GlobeNewswire) +10.09%
May-14-25 08:00AM	Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
07:00AM	Loading…
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire)
Apr-01-25 08:49AM	Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial (Clinical Trials Arena) -5.88%
Mar-31-25 08:30AM	Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial (GlobeNewswire)
Mar-25-25 08:30AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-25 08:30AM	Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +9.87%
Feb-06-25 08:16AM	Aprea Therapeutics provides update on existing patent portfolio (TipRanks)
Feb-05-25 08:00AM	Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics (GlobeNewswire)
Dec-11-24 08:30AM	Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward (GlobeNewswire)
Nov-13-24 09:55AM	Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-07-24 09:20AM	Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:40AM	Aprea Therapeutics presents preliminary results on APR-1051 (TipRanks)
Oct-23-24 08:30AM	Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire) -6.70%
Oct-14-24 08:30AM	Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-10-24 07:03PM	Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc (GuruFocus.com)
08:30AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development (GlobeNewswire)
Sep-25-24 08:00AM	Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +7.19%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-12-24 08:30AM	Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 (GlobeNewswire) +6.21%
Sep-09-24 05:15PM	UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:30AM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 09:45AM	Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-21-24 08:00AM	Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 (GlobeNewswire)
Jun-17-24 08:30AM	Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 (GlobeNewswire)
May-28-24 08:45AM	Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial (GlobeNewswire)
May-14-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.37%
08:30AM	Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-13-24 04:01PM	Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 09:15AM	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-24 12:00PM	Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire)
Mar-26-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:45AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-24 08:30AM	Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million (GlobeNewswire) -5.05%
08:29AM	Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers (GlobeNewswire)
Mar-05-24 04:45PM	Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-06-24 08:01AM	Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor (GlobeNewswire) +11.97%
Jan-30-24 08:00AM	Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 (GlobeNewswire)
Jan-04-24 04:05PM	Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 (GlobeNewswire)
Nov-09-23 04:05PM	Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -5.19%
Oct-24-23 08:00AM	Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways (GlobeNewswire)
Oct-16-23 08:30AM	Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio (GlobeNewswire)
Sep-19-23 08:00AM	Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-11-23 08:00AM	Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors (GlobeNewswire)
Sep-06-23 04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 07:30AM	Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman (GlobeNewswire)
Aug-10-23 07:30AM	Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Jun-14-23 08:00AM	Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference (GlobeNewswire)
May-30-23 08:30AM	Aprea Therapeutics to Present at BIO International Convention (GlobeNewswire) +11.76%
May-15-23 04:05PM	Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM	Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors (GlobeNewswire)
Apr-24-23 09:55AM	Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now (Zacks)
Apr-04-23 12:00PM	All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy (Zacks) -5.01%
Mar-30-23 04:05PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Mar-16-23 08:00AM	Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.26%
Mar-01-23 04:05PM	Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-27-23 04:05PM	Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-22-23 08:41PM	Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.97%
04:05PM	Aprea Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-15-23 08:00AM	Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) (GlobeNewswire)
Feb-13-23 07:00AM	Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split (GlobeNewswire)
Jan-30-23 08:00AM	Aprea Therapeutics Appoints John Hamill as Chief Financial Officer (GlobeNewswire)
Jan-19-23 08:00AM	Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit (GlobeNewswire) -7.57%
Jan-12-23 09:56AM	Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies (Zacks)
Jan-11-23 08:00AM	Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +11.99%

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Co-FounderDr. Oren Gilad Ph.D.

Senior VPMr. John P. Hamill CPA

Senior VP & Chief Scientific OfficerDr. Lars B. Abrahmsen Ph.D.

Senior Vice President of Corporate Development & StrategyMr. Brian Wiley

Head of Pharmacology DevelopmentDr. Michel Afargan Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gilad Oren	President/CEO	Jan 30 '26	Buy	0.89	28,100	25,009	373,720	Feb 02 04:08 PM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Jan 30 '26	Buy	0.89	5,700	5,073	33,433	Feb 02 04:05 PM
Duey Marc	Director	Dec 10 '25	Buy	1.17	21,459	25,000	256,155	Dec 11 08:31 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Dec 10 '25	Buy	1.17	5,000	5,825	27,733	Dec 11 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APRE

Aprea Therapeutics Inc

Upgrade your Finviz experience